All articles tagged with #de extinction
Colossal Biosciences has delayed its goal to revive the woolly mammoth to the early 2030s, citing the complexity of editing over 150 genes. The company is now relying on AI to manage the genetic data, having previously succeeded in creating woolly mice using mammoth DNA.
Thirty years after Dolly, cloning is a costly, inefficient tool—not a simple paste‑and‑copy of life—used to reproduce valuable livestock, aid conservation and advance disease research, aided by epigenetic reprogramming and the rise of induced pluripotent stem cells; while de‑extinction ideas surface, human cloning remains unsafe and tightly regulated.
Colossal Biosciences announced it hatched 26 chicks from a 3D-printed artificial eggshell as part of its de-extinction efforts to resurrect the extinct 12-foot moa. The system uses a membrane-enabled shell but omits other egg components, prompting scientists to note it is not a true artificial egg and that reviving the moa remains speculative. If progress continues, challenges include validating DNA, scaling to larger eggs, ecological fit, and ethical considerations, though the company argues the platform could aid endangered birds and embryo rescue.
Colossal Biosciences hatched 26 healthy chicks from a 3D-printed titanium artificial egg with a silicone membrane, proving a shell-free avian development system that could aid conservation and pave the way for reviving extinct birds like the moa and dodo; they aim for moa revival in New Zealand in the early- to mid-2030s, in collaboration with Ngāi Tahu and Peter Jackson, with future tests on larger eggs (emu/ostrich) to scale the technology.
Colossal Biosciences unveiled a plan to revive the extinct African bluebuck by editing roan antelope DNA and using a roan as a surrogate mother, aided by breakthroughs like roan ovum pickup and roan-derived induced pluripotent stem cells; the company hopes for a birth in coming years and a future reintroduction within the bluebuck’s historic Southern Africa range, though conservation scientists question the practical value and ecological viability of such de‑extinction efforts.
Colossal Biosciences says it has bluebuck DNA, has mapped it, and is in the final phase of genomic editing for a 2028-ish birth via a surrogate, part of a broader de-extinction portfolio aimed at re-wilding in native habitats with government and indigenous partners; critics warn of ecological risks and question practicality, while the company says the work focuses on ecosystem benefits rather than zoos.
Dallas-based Colossal Biosciences is pursuing revival of extinct species—including dire wolves and the dodo—using ancient DNA and CRISPR. The effort has drawn praise for pushing conservation tech and public engagement, but also sharp criticism from scientists who question feasibility and ecological risks, warn against conflating revived animals with extinct ones, and worry about undermining habitat protection; supporters see potential conservation benefits and genetic diversity applications, while critics urge caution and rigorous science.
Colossal Biosciences is assembling hundreds of mammoth genomes to guide edits in the Asian elephant genome, testing changes in mice before attempting embryonic cloning to produce mammoth-like calves (potentially by 2028). The project aims to restore ecological roles of mammoths and advance conservation tools, but it faces scientific and ethical debate about whether this constitutes true de-extinction and how it would be implemented in Arctic ecosystems.
Colossal Biosciences, led by Ben Lamm, claims to have made progress in de-extincting species like the dire wolf and woolly mammoth through genetic engineering, but scientists remain skeptical, arguing that these are not true resurrected species but genetically edited animals that do not fully replicate the original extinct species. Critics warn that overhyping such claims can undermine scientific trust and emphasize that traditional conservation efforts remain essential.
Scientists believe it may be possible to bring back Neanderthals within 20 years using advanced genetic engineering, but this raises significant ethical, scientific, and legal concerns, including the potential for unregulated private ventures and the moral implications of creating a new human-like species.
Scientists are close to potentially bringing back Neanderthals within 20 years using advanced genetic technologies like CRISPR, but this raises significant ethical, legal, and practical concerns, including the feasibility of the process, the well-being of any resurrected individuals, and the moral implications of creating a new human-like species. Most experts agree that such efforts are currently unwise and ethically problematic, emphasizing the importance of preserving existing human and animal species instead.
Dallas-based biotech Colossal Biosciences is making progress in de-extincting the dodo by growing primordial germ cells from pigeons, with plans to gene-edit these cells and eventually produce a dodo-like bird, highlighting advancements in avian conservation and de-extinction technology.
Colossal Biosciences has made a significant breakthrough in their effort to genetically engineer a dodo-like bird by successfully culturing primordial germ cells from pigeons, a key step towards potentially recreating the extinct species, though experts caution that true de-extinction remains scientifically complex and controversial.
Scientists at Colossal Biosciences have achieved a major breakthrough in de-extinction by successfully growing primordial germ cells from pigeons, the closest relatives of dodos, marking a pivotal step toward potentially bringing the dodo back to life within the next five to seven years using gene editing and surrogate chickens. The project aims to reintroduce the species to Mauritius, but experts caution about ecological and ethical challenges involved.
Colossal Biosciences, a biotech startup, has raised $120 million to work on resurrecting extinct animals like the dodo, with plans to achieve this within 5-7 years by growing pigeon germ cells, and has expanded its funding to over $555 million.